These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25141578)

  • 1. [Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis].
    Chrzanowska A; Batko B; Hajdyła-Banaś I; Banaś T; Krezelok M; Ludwin A
    Przegl Lek; 2014; 71(4):199-203. PubMed ID: 25141578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W
    J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
    Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
    Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
    Homer D; Nightingale P; Jobanputra P
    Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
    Kristensen LE; Saxne T; Nilsson JA; Geborek P
    Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
    Mittal N; Mittal R; Sharma A; Jose V; Wanchu A; Singh S
    Singapore Med J; 2012 Aug; 53(8):532-6. PubMed ID: 22941131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High degree of nonadherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Rauscher V; Englbrecht M; van der Heijde D; Schett G; Hueber AJ
    J Rheumatol; 2015 Mar; 42(3):386-90. PubMed ID: 25593229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study.
    Espiño-Lorenzo P; Manrique-Arija S; Ureña I; Jiménez-Núñez FG; López-Lasanta M; Romero-Barco CM; Belmonte-López MA; Irigoyen MV; Fernández-Nebro A
    Reumatol Clin; 2013; 9(1):18-23. PubMed ID: 22938792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease.
    Pasma A; Schenk CV; Timman R; Busschbach JJ; van den Bemt BJ; Molenaar E; van der Laan WH; Schrauwen S; Van't Spijker A; Hazes JM
    Arthritis Res Ther; 2015 Oct; 17():281. PubMed ID: 26449852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.